Crohn Disease Clinical Trial
Official title:
The Effect of Grapes in Inflammatory Bowel Disease
The overall objective of this pilot intervention study is to determine the impact of grape powder (46g/day freeze dried whole grape powder provided by the California Table Grape Commission) on the gut microbiotacomposition in adult patients with the IBD subtype Crohn's disease (CD).
Status | Not yet recruiting |
Enrollment | 20 |
Est. completion date | November 2, 2025 |
Est. primary completion date | September 2, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Documented diagnosis of Crohns disease. CD outpatients in remission - Harvey Bradshaw-index in remission (<6 score) - Capable of providing consent to participate. - Able to complete daily surveys and take oral nutrition - Able to record daily meal intake Exclusion Criteria: - Short bowel syndrome. - Hospitalized patients. - Individuals who lack consent capacity, including the mentally ill, prisoners, cognitively impaired participants, dementia patients. - Known drug abuse. - Known parasitic disease of the digestive system. - Symptomatic intestinal stricture. - Presence of an ostomy. - Other conditions that would be a contraindication to consumption of the study diets or preclude the participant from completing the study. - Well-founded doubt about the patients cooperation. - Existing pregnancy or lactation. - History of <1 natural bowel movements per day. - Unable to access to technology that permits the daily completion of study related activities. - Change in IBD medication within past 4 weeks. - Body mass Index <16 kg/m or =35. - Documented C.difficile colitis within four weeks of screening. - Known berry or grape allergy - No probiotic or antibiotic use for the previous 14 days |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Case Western Reserve University | California Table Grape Commission |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | fecal microbiota composition | 16S microbiome | baseline (pre-intervention), immediately after the intervention | |
Secondary | fecal myleoperoxidase (MPO) | fecal marker of inflammation | baseline (pre-intervention), immediately after the intervention | |
Secondary | fecal calprotectin | fecal marker of inflammation | baseline (pre-intervention), immediately after the intervention | |
Secondary | C-reactive protein (CRP) | blood marker of inflammation | baseline (pre-intervention), immediately after the intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04046913 -
The ADDapt Diet in Reducing Crohn's Disease Inflammation
|
N/A | |
Recruiting |
NCT05169593 -
Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy
|
Phase 4 | |
Recruiting |
NCT06116604 -
Early Bowel Resection for Terminal Ileal Crohn's Disease
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Recruiting |
NCT05627128 -
A Culturally Tailored Dietary Intervention to Treat Crohn's Disease
|
N/A | |
Recruiting |
NCT05294107 -
Intestinal Organoids
|
N/A | |
Withdrawn |
NCT04349449 -
ENTYVIO in Bio-naive Patients With Moderate/Severe Crohn's Disease (CD) in Daily Practice
|
||
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Completed |
NCT03058679 -
Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn's Disease
|
N/A | |
Completed |
NCT02871635 -
BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity
|
Phase 3 | |
Recruiting |
NCT04539665 -
Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease.
|
N/A | |
Recruiting |
NCT04266600 -
Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease
|
N/A | |
Recruiting |
NCT03913572 -
Treatment of Perianal Disease Using Adipose-derived Stem Cells
|
||
Completed |
NCT03668249 -
A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
|
||
Completed |
NCT03606499 -
Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
|
||
Terminated |
NCT04102111 -
A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease
|
Phase 2 | |
Recruiting |
NCT04997733 -
Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal
|
Phase 3 | |
Recruiting |
NCT05906576 -
Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients
|
Phase 4 | |
Not yet recruiting |
NCT04398836 -
Preoperative Nutrition for Crohn's Disease Patients
|
Phase 3 | |
Not yet recruiting |
NCT04502303 -
18F-FDG and 68Ga-FAPI PET/CT in Crohn's Disease
|
Phase 2 |